Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

An Assessment of the RIFLE Criteria for Acute Kidney Injury (AKI) and Mortality in Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS).

Gloria Mattiuzzi, MD, Amit Lahoti, Abdulla Salahudeen, Farhad Ravandi, M.D., Jorge Cortes, MD, Khanh Vu, MD, Hagop Kantarjian, MD

Blood (2009) 114 (22): 1013.

https://doi.org/10.1182/blood.V114.22.1013.1013

Published: 2009

Journal Articles

Late Relapses in Acute Myelogenous Leukemia: Analysis of Characteristics and Outcome.

Dushyant Verma, MD, FACP, Stefan Faderl, MD, Susan O’Brien, MD, Sherry Pierce, Jorge Cortes, MD, Khanh Vu, MD, Emil Freireich, MD, Michael J. Keating, MBBS, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS

Blood (2008) 112 (11): 951.

https://doi.org/10.1182/blood.V112.11.951.951

Published: 2008

Journal Articles

Effect of Tight Control of Blood Glucose during Hyper-CVAD Chemotherapy for Acute Lymphocytic Leukemia.

Khanh Vu, Sai-Ching Yeung, Deborah A. Thomas, Stefan Faderl, Marina Konopleva, Naifa Busaidy, Maria Cabanillas, Dushyant Verma, Carmen Escalante, Susan O’Brien, Victor Lavis, Hagop Kantarjian, Mary Ann Weiser

Blood (2008) 112 (11): 904.

https://doi.org/10.1182/blood.V112.11.904.904

Published: 2008

Journal Articles

Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("Augmented Hyper-CVAD") Has Activity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).

Stefan Faderl, MD, Deborah A. Thomas, MD, Farhad Ravandi, MD, Guillermo Garcia-Manero, MD, Miloslav Beran, MD PhD, Michael Rytting, MD, Charles A. Koller, MD, Srdan Verstovsek, MD PhD, Gautam Borthakur, MD, Michael Andreeff, MD PhD, Steve Kornblau, MD, Susan O’Brien, MD, Khanh Vu, MD, Monica Kwari, RN, Jennie Bretz, RN, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 4324.

https://doi.org/10.1182/blood.V110.11.4324.4324

Published: 2007

Journal Articles

Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia (ALL): The MDACC Experience with Intensified L-Asparaginase and Vincristine in Adult ALL Salvage.

Stefan Faderl, MD, Deborah A. Thomas, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Miloslav Beran, MD, PhD, Michael Rytting, MD, Charles A. Koller, MD, Srdan Verstovsek, MD, PhD, Gautam Borthakur, MD, Michael Andreeff, MD, PhD, Steve Kornblau, MD, Khanh Vu, MD, Rita Jarmon, R.N., Hagop M. Kantarjian, MD

Blood (2005) 106 (11): 1840.

https://doi.org/10.1182/blood.V106.11.1840.1840

Published: 2005

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

An Assessment of the RIFLE Criteria for Acute Kidney Injury (AKI) and Mortality in Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS).

Late Relapses in Acute Myelogenous Leukemia: Analysis of Characteristics and Outcome.

Effect of Tight Control of Blood Glucose during Hyper-CVAD Chemotherapy for Acute Lymphocytic Leukemia.

Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("Augmented Hyper-CVAD") Has Activity in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL).

Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia (ALL): The MDACC Experience with Intensified L-Asparaginase and Vincristine in Adult ALL Salvage.

Email alerts

ASH Publications

American Society of Hematology